Anti-CCDC134 Polyclonal Antibody
- 发布日期: 2020-08-10
- 更新日期: 2025-12-05
产品详请
| 产地 |
北京
|
| 品牌 |
Solarbio
|
| 货号 |
K108502P
|
| 保存条件 |
Store at -20°C. Avoid freeze / thaw cycles.
|
| 用途 |
IHC
|
| 应用范围 |
IHC
|
| 抗原来源 |
|
| CAS编号 |
|
| 保质期 |
|
| 抗体名 |
CCDC134
|
| 是否单克隆 |
否
|
| 克隆性 |
Polyclonal Antibody
|
| 靶点 |
|
| 适应物种 |
Human Mouse Rat
|
| 形态 |
|
| 宿主 |
|
| 标记物 |
|
| 包装规格 |
|
| 纯度 |
%
|
| 亚型 |
IgG
|
| 标识物 |
|
| 浓度 |
%
|
| 免疫原 |
|
| 是否进口 |
否
|
In extracellular secreted form, promotes proliferation and activation of CD8+ T cells, suggesting a cytokine-like function (PubMed:25125657). Enhances cytotoxic anti-tumor activity of CD8+ T cells (PubMed:25125657). May inhibit ERK and JNK signaling activity (PubMed:18087676, PubMed:23070808). May suppress cell migration and invasion activity, via its effects on ERK and JNK signaling (PubMed:23070808). In the nucleus, enhances stability of the PCAF histone acetyltransferase (HAT) complex member TADA2A and thus promotes PCAF-mediated H3K14 and H4K8 HAT activity. May inhibit TADA2A-mediated TP53/p53 'Lys-321' acetylation, leading to reduced TP53 stability and transcriptional activity. May also promote TADA2A-mediated XRCC6 acetylation thus facilitating cell apoptosis in response to DNA damage.